Immunome, Inc. (IMNM) vs Precigen, Inc. (PGEN)
Immunome, Inc. and Precigen, Inc. are both Biotechnology companies. Immunome, Inc. and Precigen, Inc. are of similar size ($2.8B and $2.6B). Precigen, Inc. grew revenue faster over the last twelve months: 1,875.1% against 16.7%. Immunome, Inc. has the higher net margin (0.00% vs −392.8%) and the lower return on invested capital (−3,323.0% vs −24.9%). Across the 17 metrics below, Immunome, Inc. leads on 11 and Precigen, Inc. on 6.
Valuation
Profitability
| Metric | IMNM | PGEN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 90.67% | 65.16% |
| Operating margin | 0.00% | (46.08%) | 0.00% |
| Net margin | 0.00% | (392.81%) | 0.00% |
| Free cash flow margin | 0.00% | (134.42%) | 0.00% |
| Return on equity | (64.03%) | (9,907.46%) | (57.72%) |
| Return on assets | (59.03%) | (247.40%) | (49.22%) |
| Return on invested capital | (3,322.99%) | (24.87%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack